Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Nestlé to invest up to $525M on microbiome drug

By Brian Buntz | July 1, 2021

Nestle/SeresNestlé Health Science (SWX:NESN) plans on taking a leading role in commercializing Seres Therapeutics’ (NSDQ:MCRB) experimental oral microbiome drug SER-109 for recurrent Clostridioides difficile infection (CDI).

The infection from the bacteria can lead to diarrhea and, in severe cases, severe colon damage and life-threatening inflammation. More than 20,000 Americans die each year from CDI, according to Seres Therapeutics.

SER-109 would be a first-in-class microbiome therapeutic if it wins FDA approval. It is comprised of spores of Firmicutes, a bacteria phylum.

Canaccord Genuity analyst John Newman said he expects FDA approval for SER-109 for CDI, “pending data from the safety database extension study, which we expect to be favorable and similar to Phase 3 study.”

Nestlé will first pay $175 million for shared rights to the drug and an additional $125 million if the FDA approves SER-109. Nestlé also plans to give Seres up to $225 million in potential sales milestone payments.

The alliance “provides the most effective way to get this drug to patients. That means leveraging Nestle’s infrastructure, their reach, their capabilities to serve patients more quickly, more expansively and probably ultimately more profitably than we can do ourselves,” said Seres Therapeutics CEO Eric Shaff in a company webcast.

Under the recent agreement, Seres will cover the costs of development and pre-commercialization activities and will share half of the commercial profits if the drug makes it to the market.

Nestlé Health Science had already acquired rights to Seres’ investigational treatments for CDI and inflammatory bowel disease outside of the U.S. and Canada.

SER-109 has met the primary endpoint from the pivotal Phase 3 ECOSPOR III study. Roughly 88% of patients demonstrated a sustained clinical response at week eight of that study.

In responding to an analyst’s question regarding Seres’ and Nestlé plans on how they might price the drug, Shaff pointed to the high financial toll of CDI and the limited treatment options that have historically been available. Schaff said that there are 170,000 cases of the disease each year in the U.S. and that each recurrence can cost $34,000. In addition, patients with a case of CDI can face recurrence. Schaff pointed the company’s Phase 3 trial results indicating that SER-109 can break that cycle of recurrence. “You can have a strong pharmaco-economic case to charge a price that is reflective of the value that you’re creating for the system and for the patient,” he said. “We certainly think there’s a strong case to charge a price that’s commensurate with the value that we’re creating.”

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Moving toward the autonomous lab and what’s possible today
Antheia_Logo (1)
Pharma ingredient manufacturer Antheia raises $56M Series C
Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE